Laplace Receives FDA Approval for Pivotal TRIUMPH Trial of TTVR System

In a significant advancement in cardiac care, Laplace Interventional has announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) for the TRIUMPH pivotal trial. The focus of this research is to evaluate the safety and efficacy of the company's Transcatheter Tricuspid Valve Replacement (TTVR) system in patients suffering from severe tricuspid regurgitation (TR).

Overview of the TRIUMPH Trial

The TRIUMPH trial is a prospective, multicenter study aimed at assessing Laplace's TTVR system, targeting the enrollment of approximately 400 participants across 75 locations. Participants will be randomized in a controlled fashion against standard commercial TTVR devices. In addition, the trial will include a single-arm registry of up to 150 patients who are ineligible for commercial TTVR and not suitable for transcatheter edge-to-edge repairs.

With the aim of providing new hopes for patients with advanced TR, the trial is set to generate substantial clinical data, contributing to our understanding of TTVR implications in treating this condition.

Prominent Investigators on Board

Highlighting the trial's credibility, Laplace has appointed three leading global principal investigators. They include Dr. Charanjit Rihal from the Mayo Clinic in Rochester, Dr. Kashish Goel from Vanderbilt University Medical Center in Nashville, and Dr. Brandon Jones from Providence St. Vincent Medical Center in Portland. These institutions led enrollment during the preliminary Laplace U.S. Early Feasibility Study (EFS).

Dr. Rihal expressed his enthusiasm by stating, "The safety and efficacy data demonstrated in the EFS are commendable. We eagerly anticipate further examining it in TRIUMPH, as it promises new options for patients suffering from advanced TR."

Dr. Goel echoed this optimism, noting that the approval from the FDA for the pivotal trial builds on the impressive clinical outcomes observed earlier. He remarked, "Participating in this trial aids in addressing a significant need for TR patients."

Dr. Jones added, "It's a tremendous honor to collaborate with Drs. Rihal and Goel at TRIUMPH. Our patients are looking for the next wave of transcatheter tricuspid valve treatments, and our preliminary results suggest that this unique system could accommodate a wider range of anatomical challenges, while significantly enhancing the safety profile compared to currently available devices."

Significance of FDA Approval

The receipt of FDA IDE approval marks a monumental milestone not just for Laplace Interventional, but also for the entire field of transcatheter therapy as it relates to tricuspid valve disease. Ramji Iyer, the founder and CEO of Laplace, said, "This FDA IDE approval represents a key step toward advancing treatment options for individuals battling tricuspid valve conditions. I deeply appreciate the invaluable collaboration of the investigators and everyone involved in the study, and I look forward to the clinical insights that will emerge from this pivotal research."

About Laplace Interventional

Laplace Interventional, Inc. is a privately held clinical-stage medical device company based in Minnesota, dedicated to the development of solutions for TTVR. The company aims to address the needs of over 1.6 million TR patients in the United States. The TTVR system currently remains limited to investigational use and is unavailable for commercial sale in the U.S. or elsewhere.

As the trial progresses and more data becomes available, the medical community remains hopeful that such innovative treatments could drastically improve the quality of life for countless patients suffering from tricuspid valve diseases.